Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167356 | 1.00 | HCAR2 (0.59) | HCAR2ATMAPPALOX5MAPT | |
| Propionic Acid SCHEMBL28030239 | 0.93 | HCAR2 (0.56) | HCAR2ATMAPPALOX5MAPT | |
| SCHEMBL4888226 | 0.89 | HCAR2 (0.47) | HCAR2ATMAPPALOX5MAPT | |
| SCHEMBL4888287 | 0.89 | HCAR2 (0.47) | HCAR2ATMAPPALOX5MAPT | |
| SCHEMBL24797 | 0.88 | ATM (0.70) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL1452125 | 0.86 | HCAR2 (0.62) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL4892566 | 0.86 | ATM (0.52) | HCAR2ATMAPPALOX5MAPT | |
| SCHEMBL29341 | 0.85 | HCAR2 (0.64) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL3457992 | 0.85 | HCAR2 (0.64) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL15229292 | 0.85 | HCAR2 (0.64) | HCAR2ATMAPPMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | HCAR2 824/4885ATM 3528/4885APP 3098/4885 |
| US-11046762-B2 | Cross-linkers and their uses | MTCL3, DCLRE1A, PCNA | HCAR2 824/4885ATM 3528/4885APP 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.